ArticleJAMA network open2022

Evaluation of Rituximab for Induction and Maintenance Therapy in Patients 75 Years and Older With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Sara Thietart et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.